Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8746466 | Journal of Global Antimicrobial Resistance | 2017 | 18 Pages |
Abstract
The synergy observed for some antibacterial combinations in this study supplements the currently available information for combination therapy and may suggest new directions for treating challenging cases. Some synergistic effects may be attributed, at least in part, to the ESBL-inhibitory activity of tazobactam, although this remains to be proven. The mechanisms of the other synergistic interactions observed also require further elucidation. Ceftolozane/tazobactam did not adversely affect the activity of, and was not affected by, other antibacterial agents given concurrently. In vivo studies will be needed to substantiate these results and to determine their clinical relevance.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Cédric Jacqueline, Karen Howland, Laurent Chesnel,